Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
Date:3/5/2009

VANCOUVER, March 5 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced its financial results for the fourth quarter and year ended December 31, 2008.

"During 2008 we achieved solid sales results in our Medical Products Business and were able to sustain progress on our most important new technology initiatives despite a challenging year for TAXUS," said Dr. William Hunter, President and CEO of Angiotech. "Not only did we increase Medical Products sales compared to 2007, but we were able to achieve this growth while making reductions to our operating expenses. This has been a challenging year with many factors including the turmoil in the capital and credit markets impacting our company, and under those circumstances I am proud of the results our team was able to deliver in 2008."

    Fourth Quarter Financial Highlights

    Total revenue was $62.1 million.

    -   Net product sales were $46.1 million.

    -   Royalty revenue was $15.7 million.

    -   Adjusted EBITDA (earnings before interest, taxes, depreciation and
        amortization, adjusted to exclude certain non-cash and non-recurring
        items) was $10.3 million.

    -   Research and development expenses were $7.7 million, and as adjusted
        to exclude non-cash stock-based compensation expenses and non-
        recurring termination related costs were $6.9 million. These results
        compare to $10.7 million and $8.8 million, respectively, in the third
        quarter of 2008, reflecting a reduction in expenses of 21.6% in a
        single quarter on an adjusted basis. This reduction is in addition to
        the 49% reduction in research and development expenses already
        reported in the third quarter as compared to the second quarter of
        2008.

    -   Selling, general and administrative expenses were $21.4 million, and
        as adjusted to exclude non-cash stock-based compensation expenses,
        non-recurring termination related costs and intellectual property
        litigation costs, were $19.0 million. These results compare to $23.4
        million and $20.5 million, respectively, in the third quarter of 2008
        and to $26.8 million and $23.5 million, respectively, in the
        comparable period of 2007. Importantly, we were able to achieve
        higher sales during 2008 on lower absolute levels of selling, general
        and administrative expenses as compared to 2007.

    -   GAAP net loss and net loss per share from continuing operations for
        the quarter were $77.0 million and $0.90, respectively, compared to
        $27.9 million and $0.29 for the fourth quarter of 2007. The increase
        in the net loss of $49.1 million is due primarily to a write-down of
        goodwill recorded during the quarter. Under GAAP, circumstances that
        could indicate a "goodwill impairment" include significant declines
        in a company's share price, adverse changes or outcomes in legal or
        regulatory matters, technological advances that may significantly
        impact a company's or a partner's products or services, or
        unanticipated competition. Due to the continued decline in our market
        value in the fourth quarter of 2008 and the further negative
        indicators for the capital markets and the economy as a whole, we
        updated our impairment tests of goodwill and acquired intangible
        assets and concluded a further impairment had occurred in the
        carrying amounts of goodwill associated with both our Medical
        Products and Pharmaceutical Technologies segments. Accordingly, we
        recorded an impairment charge to goodwill, which is a non-cash
        accounting item, of $50.3 million in the fourth quarter of 2008, in
        addition to the write-down of goodwill of $599.4 million recorded in
        the third quarter of 2008, leaving no goodwill on our books as of
        December 31, 2008.

    -   As of December 31, 2008, cash, short and long-term investments were
        $41.4 million and net debt was $535.2 million.

Significant Recent Developments

New Senior Secured Credit Facilities. On March 2, 2009 we announced that we had completed a financing transaction with Wells Fargo Foothill, LLC. The financing includes a delayed draw secured term loan facility of up to $10 million, and a secured revolving credit facility with a borrowing base derived from the value of certain of the Company's finished goods inventory and accounts receivable, providing up to an additional $22.5 million in available credit, subject to certain terms and conditions. Any borrowings outstanding under the term loan and revolving credit facility bear interest ranging from LIBOR + 3.25% to LIBOR +3.75%, with a minimum Base LIBOR Rate of 2.25%. The term loan and the revolving credit facility include certain covenants and restrictions with respect to our operations, require us to maintain certain levels of Adjusted EBITDA and interest coverage ratios, among other terms and conditions, and are secured by the assets of the Company and its Canadian and U.S. subsidiaries. The purpose of the financings is to provide additional liquidity and capital resources for working capital and general corporate purposes.

Financial and Strategic Alternatives Process. During approximately the last eight calendar quarters, our royalty revenue has declined significantly, primarily due to lower than expected royalties derived from sales by our partner Boston Scientific Corporation ("BSC") of TAXUS(R) coronary stent systems. This decline in royalty revenue has significantly impacted our ability to fund our operations and service our debt obligations, and has impacted our liquidity position. During 2008, our management and Board of Directors determined to explore and pursue various restructuring and cost reduction initiatives in order to conserve our liquidity, as well as various financial and strategic transactions that could potentially reduce or eliminate our existing debt obligations and improve our working capital position.

On July 7, 2008, we announced that our Board of Directors had authorized a transaction to create a new subsidiary, Angiotech Pharmaceutical Interventions Inc. ("API"), and that we would contribute certain business assets and intellectual property to API, primarily consisting of business assets of Angiotech other than the intellectual property and royalty revenue related to TAXUS(R) coronary stent systems. In connection with this transaction, we were to receive $200 to $300 million of new financing from new investors to establish API, which financing was targeted to reduce substantial amounts of our existing debt obligations with equivalent amounts of convertible debt bearing interest in additional equity of the newly created subsidiary in kind, as opposed to cash. This transaction, if approved by our shareholders and completed, would have substantially reduced our annual cash pay interest obligations.

On September 22, 2008, we announced that we had postponed the planned shareholder vote regarding the proposed API transaction. As of that date, given the time required for more extended discussions to address concerns of certain of our shareholders and bondholders, and given various other factors impacting our business and cash position (including lower expected revenues derived from BSC), we did not believe we would be able to satisfy the transaction condition with respect to the minimum level of cash and cash equivalents required to be held at the time of the transaction's close.

On September 22, 2008, we also announced that we would pursue various initiatives to reduce operating costs and further focus our business efforts. Our remaining resources subsequent to these initiatives have been focused primarily on our existing medical device products business, with particular emphasis on certain existing product brands and on selected new products that have recently launched, including Quill(TM) SRS and the HemoStream(TM) Chronic Dialysis Catheter.

Since the September 22 announcement, Angiotech and its Board of Directors have been pursuing other financing alternatives to address the Company's working capital needs for its business initiatives, as well as to address potential liquidity issues that may arise relating to our current balance sheet structure.

On November 12, 2008, the API transaction was terminated. On November 21, 2008, we announced that we had engaged the Blackstone Group to assist us in exploring various alternatives for our business and capital structure, including, but not limited to, the secured senior secured financing facilities discussed above, assisting us in exploring various financial and strategic alternatives that could generate significant capital to facilitate our ability to refinance, reduce or eliminate our existing indebtedness, evaluating various restructuring alternatives to pursue with the holders of our Senior Floating Rate Notes due 2013 and our 7.75% Senior Subordinated Notes due 2014 and assisting us in evaluating proposals or potential proposals from various financial parties regarding a significant investment of capital.

Our cash inflows and the amounts of expenditures that will be necessary to execute our business plan are subject to numerous uncertainties, including but not limited to: changes in drug-eluting coronary stent markets, including the impact of new competitive entrants into such markets, and the sales achieved in such markets by our partner BSC, the timing and success of product sales and marketing initiatives and new product launches, the timing and success of our research, product development and clinical trial activities, the timing of completing certain operational initiatives, our ability to effect reductions in certain aspects of our budgets in an efficient and timely manner, and changes in interest rates. These and other uncertainties may adversely affect our liquidity and capital resources to a significant extent and may force us to further reduce our expenditures on research and development or on our various new product and sales and marketing initiatives in order for us to continue to service our debt obligations. Such further reductions in our budgeted expenditures may have an adverse effect on our new product development and sales growth initiatives and reduce our ability to achieve the revenue growth targets, product launch or new product development timelines in our current operating plan. There can also be no assurance that such reductions in expenditures will be adequate to provide enough cash flow to continue to service our current level of debt obligations.

In particular, should our royalties received from BSC decline more significantly than we expect in future periods as a result of new competitive entrants into the U.S. drug-eluting stent market, our liquidity may be adversely affected, and we may be forced to explore alternative funding sources through debt, equity or other public or private securities offerings, or to pursue certain reorganization, restructuring or other strategic alternatives. There can be no assurance that if we pursue such financing activities that alternative sources of funding would be available to us on attractive terms, if at all. In addition, we may not be able to complete any restructuring, reorganization or strategic activities on terms that would be favorable for us or our shareholders. Capital markets conditions have deteriorated significantly during 2008 and 2009, including a significant and material decline in the level of corporate lending activity, combined with a significant increase in the cost of any such lending. Current market conditions may have a material impact on our ability to secure any alternative source of funding, our ability to secure interim financing or to complete any of the activities as described on favorable terms, if at all.

Fourth Quarter Business Highlights

Promoted Brand Strategy. Sales of our currently marketed Promoted Brand products continued to demonstrate higher revenue growth as compared to our overall product portfolio, consistent with recent prior quarters. Revenue growth in our Promoted Brand products was approximately 39%, contributing to an aggregate growth rate of approximately 6% in total product revenue in the fourth quarter of 2008 as compared to the fourth quarter of 2007. Revenue growth was approximately 46% for our Promoted Brand products, and 12% for all products, respectively, for the full year 2008 as compared to 2007. We observed continued commercial progress with our proprietary Quill SRS product line in the fourth quarter. At the end of the quarter, we had 596 hospital customers, which exceeded our goal of 500 hospital customers by the end of 2008.

Base Medical Products Sales. Sales of products outside of our Promoted Brand product group were stable during the quarter and indicated growth year over year. Revenue growth in our base Surgical, Interventional and Specialties businesses (excluding Promoted Brands) was approximately flat in the fourth quarter of 2008 as compared to the same period in 2007, and approximately 6% for the full year 2008 as compared to 2007.

FDA Approval Received by our Partner BSC for TAXUS Liberte(R) and TAXUS Express Atom(TM) Stents. On October 10, 2008, we announced that BSC had received approval from the United States Food and Drug Administration ("FDA") to market and sell the second generation TAXUS Liberte(R) Paclitaxel-Eluting Coronary Stent System in the United States. On September 25, 2008, we announced that BSC had received approval from the FDA to market and sell the Taxus Express2 Atom(TM) Paclitaxel-Eluting Coronary Stent System in the United States. We are entitled to receive royalties based on the commercial sale of these products by BSC.

Enrollment Completed for TAXUS PERSEUS Clinical Trial. On October 8, 2008, we announced that BSC had completed enrollment in the PERSEUS clinical trial, designed to evaluate the third-generation TAXUS Element paclitaxel-eluting coronary stent. The PERSEUS clinical program has enrolled nearly 1,500 patients at 100 U.S. and international centers since July 2007, and will compare the TAXUS Element Stent to the prior-generation TAXUS Express2 Stent marketed in the United States since 2004.

    Financial Information
    ----------------------

This press release contains the condensed financial statements derived from the audited consolidated financial statements for the year ended December 31, 2008 and 2007. Full audited consolidated financial statements and Management's Discussion and Analysis for the year ended December 31, 2008, will be filed on Form 10-K on or before March 16, 2009.

Amounts, unless specified otherwise, are expressed in U.S. dollars. Financial results are reported under U.S. Generally Accepted Accounting Principals ("GAAP") unless otherwise noted. All per share amounts are stated on a diluted basis unless otherwise noted.

    Use of Certain Non-GAAP Financial Measures
    -------------------------------------------

Certain financial results presented in this press release include non-GAAP measures that exclude certain items. Adjusted net loss from continuing operations, adjusted net loss per share from continuing operations and adjusted earnings before interest, taxes, depreciation and amortization ("Adjusted EBITDA") exclude certain non-cash and non-recurring items such as, goodwill and financing charges, write downs, acquisition related amortization charges, acquired in-process research and development relating to license agreements and acquisitions, stock-based compensation expense, foreign exchange gains or losses relating to translation of foreign denominated items and other non-recurring items. Adjusted net loss from continuing operations, adjusted net loss per share from continuing operations and Adjusted EBITDA also exclude litigation expenses related to defending intellectual property claims. Revenue, as adjusted, excludes non-recurring, non-operating revenue derived from license agreements and other license revenue, net of license fees due to licensors and excludes amounts accrued for costs incurred. Adjusted net loss from continuing operations, adjusted net loss per share from continuing operations, revenue, as adjusted, and Adjusted EBITDA do not have any standardized meaning prescribed by GAAP and therefore may not be comparable to similar measures presented by other issuers. Management uses these non-GAAP or adjusted operating measures to establish operational goals and believes that these measures may assist investors in evaluating the results of the business and analyzing the underlying trends in our business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for, or as superior to, financial reporting measures prepared in accordance with GAAP. We have provided a reconciliation of these measures to GAAP in the attached tables.

    Conference Call Information
    ----------------------------
    A conference call to discuss these financial results will be held today,
Thursday March 5, 2009 at 7:00 AM PT (10:00 AM ET).

    Dial-in information:
    North America (toll-free): (800) 291-9234
    International: (617) 614-3923
    Enter passcode: 52474180

    A replay archive of the conference call will be available until March 12,
2009 by calling (888) 286-8010 (in North America) or (617) 801-6888
(International) and entering passcode 36405359.
    A live webcast will be available to all interested parties through the
Investors section of Angiotech's website: www.angiotech.com



                       ANGIOTECH PHARMACEUTICALS, INC.
                 CONDENSED CONSOLIDATED STATEMENTS OF INCOME
                                 (Unaudited)

    (in thousands of U.S.$, except              Three months ended
     share and per share data)                   December 31, 2008
    -------------------------------------------------------------------------
                                         Reported     Adjustments   Adjusted
    REVENUE
    Royalty revenue                     $  15,676    $       -     $  15,676
    Product sales, net                     46,054            -        46,054
    License fees                              352         (352) b          -
    -------------------------------------------------------------------------
                                           62,082         (352)       61,730
    -------------------------------------------------------------------------

    EXPENSES
    License and royalty fees                2,774            -         2,774
    Cost of products sold                  23,622            -        23,622
    Research and development                7,723         (776) d      6,947
    Selling, general and administrative    21,381       (2,420) e     18,961
    Depreciation and amortization           8,421       (7,460) f        961
    In-process research and development         -            -             -
    -------------------------------------------------------------------------
                                           63,921      (10,656)       53,265
    -------------------------------------------------------------------------
    Operating (loss) income                (1,839)      10,304         8,465
    -------------------------------------------------------------------------

    Other income (expenses):
    Foreign exchange gain (loss)           (1,032)       1,032  h          -
    Investment and other income              (498)         544  i         46
    Interest expense on long-term debt    (10,639)         559  j    (10,080)
    Write-down and other deferred
     financing charges                     (3,000)       3,000  k          -
    Write-down / loss on redemption of
     investments                          (10,964)      10,964  l          -
    Write-down of assets held for sale     (1,283)       1,283  m          -
    Write-down of goodwill                (50,285)      50,285  n          -
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
                                          (77,701)      67,667       (10,034)
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------

    (Loss) income from continuing
     operations before income taxes       (79,540)      77,971        (1,569)
    Income tax (recovery) expense          (2,577)       3,629  o      1,052
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------

    (Loss) income from continuing
     operations                           (76,963)      74,342        (2,621)
    Net loss from discontinued
     operations, net of income taxes            -            -             -
    -------------------------------------------------------------------------

    Net (loss) income for the period    $ (76,963)   $  74,342     $  (2,621)
    -------------------------------------------------------------------------

    Basic and diluted net loss per
     common share from continuing
     operations                         $   (0.90)                 $   (0.03)
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------

    Weighted average shares
     outstanding (000's) - basic and
     diluted                               85,118                     85,118
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------


    (in thousands of U.S.$, except               Three months ended
     share and per share data)                    December 31, 2007
    -------------------------------------------------------------------------
                                         Reported     Adjustments   Adjusted
    REVENUE
    Royalty revenue                     $  27,158    $       -     $  27,158
    Product sales, net                     43,935         (401) a     43,534
    License fees                              266         (266) b          -
    -------------------------------------------------------------------------
                                           71,359         (667)       70,692
    -------------------------------------------------------------------------

    EXPENSES
    License and royalty fees                4,527            -         4,527
    Cost of products sold                  23,578          (85) c     23,493
    Research and development               13,556         (150) d     13,406
    Selling, general and administrative    26,782       (3,276) e     23,506
    Depreciation and amortization           8,826       (7,993) f        833
    In-process research and development       125         (125) g          -
    -------------------------------------------------------------------------
                                           77,394      (11,629)       65,765
    -------------------------------------------------------------------------
    Operating (loss) income                (6,035)      10,962         4,927
    -------------------------------------------------------------------------

    Other income (expenses):
    Foreign exchange gain (loss)              173         (173) h          -
    Investment and other income               511          155  i        666
    Interest expense on long-term debt    (12,774)         558  j    (12,216)
    Write-down and other deferred
     financing charges                          -            -             -
    Write-down / loss on redemption of
     investments                                -            -             -
    Write-down of assets held for sale          -            -             -
    Write-down of goodwill                      -            -             -
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
                                          (12,090)         540       (11,550)
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------

    (Loss) income from continuing
     operations before income taxes       (18,125)      11,502        (6,623)
    Income tax (recovery) expense           6,788        3,626  o     10,414
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------

    (Loss) income from continuing
     operations                           (24,913)       7,876       (17,037)
    Net loss from discontinued
     operations, net of income taxes       (2,946)       2,946             -
    -------------------------------------------------------------------------

    Net (loss) income for the period    $ (27,859)   $  10,822     $ (17,037)
    -------------------------------------------------------------------------

    Basic and diluted net loss per
     common share from continuing
     operations                         $   (0.29)                 $   (0.20)
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------

    Weighted average shares
     outstanding (000's) - basic and
     diluted                               85,030                     85,030
    -------------------------------------------------------------------------
    a.  Amounts accrued for costs incurred, and potential future costs,
        related to our offer to accept returns of Contour Threads brand
        product as part of consolidation and discontinuation of the Contour
        Threads brand name, coincident with the launch of our Quill SRS brand
        name.
    b.  Non-recurring, non-operating license revenue.
    c.  Change in estimate of accounting for excess and obsolete inventory
        resulting from the alignment during the fourth quarter of 2007 of
        inventory policies across our various manufacturing operations.
    d.  Research and development adjustments:
        ---------------------------------------------------------------------
                                                 Three months   Three months
                                                    ended          ended
                                                 Dec 31, 2008  Dec. 31, 2007
                                                 ------------- --------------
        Stock-based compensation                     $   (125)      $   (150)
        Termination and reorganization costs             (338)             -
        Non-recurring research and development
         expenses and intellectual property license
         agreement                                       (313)             -
        ---------------------------------------------------------------------
                                                     $   (776)      $   (150)
                                                 ------------- --------------

    e.  Selling, general and administrative adjustments:
        ---------------------------------------------------------------------
                                                 Three months   Three months
                                                    ended          ended
                                                 Dec 31, 2008   Dec 31, 2007
                                                 -------------  -------------
        Stock-based compensation                     $   (333)      $   (721)
        Termination and reorganization costs           (1,245)        (3,526)
        Litigation expenses relating to defending
         intellectual property claims                    (177)           971
        Non-recurring financing fees                     (665)             -
        ---------------------------------------------------------------------
                                                     $ (2,420)      $ (3,276)
                                                 -------------  -------------

    f.  Amortization of acquisition related intangible assets and medical
        technologies.
    g.  Non-recurring in-process research and development expense relating to
        payments made to licensors and collaborators.
    h.  Foreign exchange fluctuations on foreign currency net monetary
        assets.
    i.  Realized loss on disposition of assets and other capitalized costs.
    j.  Amortization of deferred financing costs.
    k.  Write-down of other deferred financing charges.
    l.  Realized loss on disposition of investment and unrealized loss on
        write-down of investments.
    m.  Loss on write-down of assets classified as held for sale.
    n.  Loss on write-down of goodwill.
    o.  Tax effects of adjustments a. through n. for the period, including
        the reversal of tax reserves previously booked.



                       ANGIOTECH PHARMACEUTICALS, INC.
                 CONDENSED CONSOLIDATED STATEMENTS OF INCOME
                                 (Unaudited)


    (in thousands of U.S.$, except                    Year ended
     share and per share data)                    December 31, 2008
    -------------------------------------------------------------------------
                                         Reported     Adjustments   Adjusted
    REVENUE
    Royalty revenue                     $  91,546    $       -     $  91,546
    Product sales, net                    190,816            -       190,816
    License fees                              910         (910) b          -
    -------------------------------------------------------------------------
                                          283,272         (910)      282,362
    -------------------------------------------------------------------------

    EXPENSES
    License and royalty fees               14,258            -        14,258
    Cost of products sold                 101,052         (122) c    100,930
    Research and development               53,192       (5,535) d     47,657
    Selling, general and administrative    98,483      (11,959) e     86,524
    Depreciation and amortization          33,998      (30,219) f      3,779
    In-process research and development     2,500       (2,500) g          -
    -------------------------------------------------------------------------
                                          303,483      (50,335)      253,148
    -------------------------------------------------------------------------
    Operating (loss) income               (20,211)      49,425        29,214
    -------------------------------------------------------------------------

    Other income (expenses):
    Foreign exchange gain (loss)              540         (540) h          -
    Investment and other income             1,192          668  i      1,860
    Interest expense on long-term debt    (44,490)       2,236  j    (42,254)
    Write-down and other deferred
     financing charges                    (16,544)      16,544  k          -
    Write-down / loss on redemption of
     investments                          (23,587)      23,587  l          -
    Write-down of assets held for sale     (1,283)       1,283  n          -
    Write-down of goodwill               (649,685)     649,685  o          -
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
                                         (733,857)     693,463       (40,394)
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------

    (Loss) income from continuing
     operations before income taxes      (754,068)     742,888       (11,180)
    Income tax (recovery) expense         (12,892)      19,919  p      7,027
    -------------------------------------------------------------------------

    (Loss) income from continuing
     operations                          (741,176)     722,969       (18,207)
    Net loss from discontinued
     operations, net of income taxes            -            -             -
    -------------------------------------------------------------------------

    Net (loss) income for the period    $(741,176)   $ 722,969     $ (18,207)
    -------------------------------------------------------------------------

    Basic and diluted net (loss)
     income per common share from
     continuing operations              $   (8.71)                 $   (0.21)
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------

    Weighted average shares
     outstanding (000's) - basic and
     diluted                               85,118                     85,118
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------


    (in thousands of U.S.$, except                    Year ended
     share and per share data)                    December 31, 2007
    -------------------------------------------------------------------------
                                         Reported     Adjustments   Adjusted

    REVENUE
    Royalty revenue                     $ 116,659    $       -     $ 116,659
    Product sales, net                    170,193        2,579  a    172,772
    License fees                              842         (842) b          -
    -------------------------------------------------------------------------
                                          287,694        1,737       289,431
    -------------------------------------------------------------------------

    EXPENSES
    License and royalty fees               18,652            -        18,652
    Cost of products sold                  94,949       (2,065) c     92,884
    Research and development               53,963       (4,582) d     49,381
    Selling, general and administrative    99,315      (16,470) e     82,845
    Depreciation and amortization          33,429      (29,971) f      3,458
    In-process research and development     8,125       (8,125) g          -
    -------------------------------------------------------------------------
                                          308,433      (61,213)      247,220
    -------------------------------------------------------------------------
    Operating (loss) income               (20,739)      62,950        42,211
    -------------------------------------------------------------------------

    Other income (expenses):
    Foreign exchange gain (loss)             (341)         341  h          -
    Investment and other income            10,393       (5,422) i      4,971
    Interest expense on long-term debt    (51,748)       2,242  j    (49,506)
    Write-down and other deferred
     financing charges                          -            -             -
    Write-down / loss on redemption of
     investments                           (8,157)       8,157  m          -
    Write-down of assets held for sale          -            -             -
    Write-down of goodwill                      -            -             -
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
                                          (49,853)       5,318       (44,535)
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------

    (Loss) income from continuing
     operations before income taxes       (70,592)      68,268        (2,324)
    Income tax (recovery) expense         (14,545)      18,066  p      3,521
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------

    (Loss) income from continuing
     operations                           (56,047)      50,202        (5,845)
    Net loss from discontinued
     operations, net of income taxes       (9,893)       9,893             -
    -------------------------------------------------------------------------

    Net (loss) income for the period    $ (65,940)   $  60,095     $  (5,845)
    -------------------------------------------------------------------------

    Basic and diluted net (loss)
     income per common share from
     continuing operations              $   (0.66)                 $   (0.07)
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------

    Weighted average shares
     outstanding (000's) - basic and
     diluted                               85,015                     85,015
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
    a.  Amounts accrued for costs incurred, and potential future costs,
        related to our offer to accept returns of Contour Threads brand
        product as part of consolidation and discontinuation of the Contour
        Threads brand name, coincident with the launch of our Quill SRS brand
        name.
    b.  Non-recurring, non-operating license revenue.
    c.  Severances and reorganization costs. In 2007, change in estimate of
        accounting for excess and obsolete inventory resulting from the
        alignment during the second quarter of 2007 of inventory policies
        across our various manufacturing operations.
    d.  Research and development adjustments:
        ---------------------------------------------------------------------
                                                   Year-ended     Year-ended
                                                 Dec 31, 2008   Dec 31, 2007
                                                 -------------  -------------
        Stock-based compensation                         (795)        (1,665)
        License fees due to licensors related
         to non-recurring license revenue                   -           (419)
        Termination and reorganization costs           (3,302)          (849)
        Non-recurring supply / distribution
         agreement termination costs                     (500)          (899)
        Non-recurring research and development
         expenses and intellectual property
         license agreement.                              (938)          (750)
        ---------------------------------------------------------------------
                                                       (5,535)        (4,582)
                                                 -------------  -------------

    e.  Selling, general and administrative adjustments:
        ---------------------------------------------------------------------
                                                   Year-ended     Year-ended
                                                 Dec 31, 2008   Dec 31, 2007
                                                 -------------  -------------
        Stock-based compensation                       (1,641)        (2,924)
        Termination and reorganization costs           (6,983)        (8,365)
        Litigation expenses relating to
         defending intellectual property claims        (2,670)        (4,931)
        Non-recurring financing fees                     (665)             -
        Non-recurring supply / distribution
         agreement termination costs                        -           (250)
        ---------------------------------------------------------------------
                                                      (11,959)       (16,470)
                                                 -------------  -------------

    f.  Amortization of acquisition-related intangible assets and medical
        technologies.
    g.  Non-recurring in-process research and development expense relating to
        payments made to licensors and collaborators.
    h.  Foreign exchange fluctuations on foreign currency net monetary
        assets.
    i.  Realized loss on disposition of assets and unrealized loss on write-
        down of an intangible asset. In 2007, write-off of uncollectible
        receivable and write-off of certain capitalized costs, net of gain
        realized on recovery of investments.
    j.  Amortization of deferred financing costs.
    k.  Write-down of other deferred financing charges.
    l.  Realized loss on disposition of investment and unrealized loss on
        write-down of investments.
    m.  Net impact of loss and gain on redemption of investments of common
        share holdings in Orthovita Inc. and NuVasive Inc. respectively.
    n.  Loss on write-down of assets classified as held for sale.
    o.  Loss on write-down of goodwill.
    p.  Tax effects of adjustments a. through o. for the period, including
        the reversal of tax reserves previously booked.



                       ANGIOTECH PHARMACEUTICALS, INC.
                       CALCULATION OF ADJUSTED EBITDA
                                 (Unaudited)

                              Three months ended                  Year ended
    (in thousands                    December 31,                December 31,
     of U.S.$)                2008          2007          2008          2007
    -------------------------------------------------------------------------

    Net loss on a GAAP
     basis             $   (76,963)  $   (27,859)  $  (741,176)  $   (65,940)
    Interest expense
     on long-term debt      10,639        12,774        44,490        51,748
    Income tax expense
     (recovery)             (2,577)        9,734       (12,892)      (16,152)
    Depreciation and
     amortization            9,327         9,902        38,174        37,907
    -------------------------------------------------------------------------
    EBITDA                 (59,574)        4,551      (671,404)        7,563
    Adjustments:

    Net loss from
     discontinued
     operations,
     excluding
     depreciation,
     amortization and
     income tax
     expense included
     above                       -             -             -        11,122
    In-process research
     and development             -           125         2,500         8,125
    Non-recurring
     research and
     development               313             -           938           750
    Non-recurring
     revenue, net of
     license fees             (353)         (266)         (912)         (426)
    Stock-based
     compensation              458           871         2,439         4,588
    Litigation expenses        177          (971)        2,670         4,931
    Foreign exchange
     loss (gain)             1,032          (173)         (540)          340
    Investment and other
     income                    498          (511)       (1,255)       (4,814)
    Severance                1,583         3,526        10,407         8,964
    Supply/distribution
     agreement
     termination costs           -             -             -         2,199
    E&O inventory
     adjustment                  -           665             -         2,645
    Contour Threads
     return costs
     accrual                     -             -             -         2,579
    Write off of
     capitalized costs           -          (981)          500          (300)
    Write off
     uncollectible
     tax receivable              -             -             -         2,250
    Gain realized on
     recovery of
     investment                  -             -             -        (7,510)
    Accrued interest
     income                      -             -             -          (597)
    Non-recurring
     financing costs           665             -           665             -
    Write-down and
     other deferred
     financing charges       3,000             -        16,544             -
    Write-down / loss
     on redemption of
     investments            10,964             -        23,587         8,157
    Write-down of
     assets held for
     sale                    1,283             -         1,283             -
    Write-down of
     goodwill               50,285             -       649,685             -
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
    Adjusted EBITDA    $    10,331   $     6,836   $    37,107   $    50,566
    -------------------------------------------------------------------------



                       ANGIOTECH PHARMACEUTICALS, INC.
                    CONDENSED CONSOLIDATED BALANCE SHEETS
                                 (Unaudited)

    As at                                          December 31,  December 31,
    (in thousands of U.S.$)                               2008          2007
    -------------------------------------------------------------------------
    ASSETS
    Cash and short-term investments                $    39,800   $   109,225
    Accounts receivable                                 25,524        22,678
    Inventories                                         38,594        33,647
    Deferred income taxes                                3,820         5,964
    Other current assets                                 5,234         7,070
    -------------------------------------------------------------------------
    Total current assets                               112,972       178,584
    -------------------------------------------------------------------------
    Long-term investments                                1,561         6,557
    Assets held for sale                                 8,422             -
    Property and equipment, net                         49,108        59,187
    Intangible assets, net                             195,477       225,889
    Goodwill                                                 -       659,511
    Deferred financing costs                            11,363        13,600
    Other assets                                         6,294         6,780
    -------------------------------------------------------------------------
    Total assets                                   $   385,197   $ 1,150,108
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------

    LIABILITIES AND SHAREHOLDERS' (DEFICIT) EQUITY
    Current liabilities                            $    61,415   $    62,940
    Long-term debt                                     575,000       575,000
    Deferred income taxes                               40,577        59,368
    Other tax liabilities                                3,145         4,693
    Other long-term liabilities                          4,933         6,035
    Stockholders' (deficit) equity                    (299,873)      442,072
    -------------------------------------------------------------------------
    Total liabilities and stockholders'
     (deficit) equity                              $   385,197   $ 1,150,108
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------


    Forward Looking Statements
    --------------------------

Statements contained in this press release that are not based on historical fact, including without limitation statements containing the words "believes," "may," "plans," "will," "estimates," "continues," "anticipates," "intends," "expects" and similar expressions, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities laws. All such statements are made pursuant to the "safe harbor" provisions of applicable securities legislation. Forward-looking statements may involve, but are not limited to, comments with respect to our objectives and priorities for 2009 and beyond, our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research, development, product and drug development. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions, both nationally and in the regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; adverse results or unexpected delays in pre-clinical and clinical product development processes; adverse findings related to the safety and/or efficacy of our products or products sold by our partners; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development and to expand manufacturing and commercialization activities or consummate acquisitions; and any other factors that may affect performance. In addition, our business is subject to certain operating risks that may cause the actual results expressed or implied by the forward-looking statements in this press release to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the continued availability of capital to finance our activities; and any other factors referenced in our other filings with the SEC and applicable Canadian regulatory authorities. For a more thorough discussion of the risks associated with our business, see the "Risk Factors" section in our annual report for the year ended December 31, 2007 filed with the SEC on Form 40-F and our quarterly report for the three months ended September 30, 2008 filed with the SEC on Form 10-Q.

Given these uncertainties, assumptions and risk factors, readers are cautioned not to place undue reliance on such forward-looking statements. Except as required by law, we disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained in this press release to reflect future results, events or developments.

(C)2009 Angiotech Pharmaceuticals, Inc. All Rights Reserved.

About Angiotech Pharmaceuticals

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX: ANP), please visit our website at www.angiotech.com.


'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved


Related biology technology :

1. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
2. Angiotech Pharmaceuticals announces time change of conference call and webcast
3. Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners
4. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
5. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
6. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
7. Angiotech wins before the UK House of Lords
8. Angiotech to Establish Separate Operating and Royalty Businesses
9. Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
10. Angiotech announces market launch of Quill(TM) SRS MONODERM(TM)
11. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... February 08, 2016 , ... Franz Inc. ... Graph Database technology, today announced the availability of AllegroGraph 6, the leading Semantic ... Cloudera Certified Technology Program (CCPT). AllegroGraph is the first Semantic Graph ...
(Date:2/8/2016)... has an active R&D program for the development ... the Group has a unique research and development center in ... developing Bio Control products. Stockton has ... and regulatory guidelines, and is active in more than 35 ... Stockton,s flagship product Timorex Gold ® ...
(Date:2/8/2016)... 2016 --> ... "Company"), the ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today announces ... trachomatis (CT) test to be launched on the Company,s io® ... the CT test is now cleared for sale within the ... The launch of the io® CT test signals a new ...
(Date:2/6/2016)... ... February 06, 2016 , ... Contact:, ... Center for Excellence in Education Sponsors Teacher Training Program , Bite of Science ... – The Center for Excellence in Education (CEE) will sponsor a Bite of ...
Breaking Biology Technology:
(Date:1/20/2016)... A market that just keeps on growing. ... explosion in genomics knowledge. Learn all about it in ... of dynamic trends are pushing market growth and company ... pharmacogenomics - pathogen evolution - next generation sequencing - ... understanding of the role of genetic material in Disease ...
(Date:1/18/2016)... Calif. , Jan. 18, 2016  Extenua ... software that simplifies the use and access of ... and go-to-market partnership with American Cyber.  ... brings extensive experience leading transformational C4ISR and Cyber ... and integrating the latest proven technology solutions," said ...
(Date:1/13/2016)... DUBLIN , January 13, 2016 ... has announced the addition of the  ... - Estimation & Forecast (2015-2020)" ... http://www.researchandmarkets.com/research/7h6hnn/india_biometrics ) has announced the ... & Identification Market - Estimation & ...
Breaking Biology News(10 mins):